PDCD1 and acute myeloid leukemia: Based on these findings, we speculate that the combination of anti-PD-1 antibodies with conventional chemotherapy and HMAs may overcome drug resistance, enhance anti-tumor activity, and thereby further improve the therapeutic efficacy in treating r/r AML.